[1]王玉龙,张美荣,周 昱.乳腺癌患者血清微小RNA-135b、微小RNA-148a-3p、微小RNA-186-5p表达水平及其与新辅助化疗效果相关性研究[J].陕西医学杂志,2024,(5):684-687,691.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.024]
　WANG Yulong,ZHANG Meirong,ZHOU Yu.Levels of serum miR-135b,miR-148a-3p and miR-186-5p in breast cancer patients and their correlation with the effect of neoadjuvant chemotherapy[J].,2024,(5):684-687,691.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.024]
点击复制

乳腺癌患者血清微小RNA-135b、微小RNA-148a-3p、微小RNA-186-5p表达水平及其与新辅助化疗效果相关性研究
分享到：

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
期数:
2024年5期
页码:
684-687,691
栏目:
临床检验
出版日期:
2024-05-05

文章信息/Info

Title:
Levels of serum miR-135b,miR-148a-3p and miR-186-5p in breast cancer patients and their correlation with the effect of neoadjuvant chemotherapy
作者:
王玉龙1; 2; 张美荣3; 周 昱4
(1.佳木斯大学临床医学院,黑龙江 佳木斯 154007; 2.齐齐哈尔医学院附属第二医院,黑龙江 齐齐哈尔 161000; 3.齐齐哈尔市第一医院,黑龙江 齐齐哈尔 161005; 4.佳木斯大学附属第一医院,黑龙江 佳木斯 154007)
Author(s):
WANG Yulong; ZHANG Meirong; ZHOU Yu
(School of Clinical Medicine,Jiamusi University,Jiamusi 154007,China)
关键词:
乳腺癌;  微小RNA-135b;  微小RNA-148a-3p;  微小RNA-186-5p;  新辅助化疗;  相关性研究
Keywords:
Breast cancer;  miR-135b;  miR-148a-3p;  miR-186-5p;  Neoadjuvant chemotherapy;  Correlation study
分类号:
R 737.9
DOI:
DOI:10.3969/j.issn.1000-7377.2024.05.024
文献标志码:
A
摘要:
目的:探讨乳腺癌患者血清微小RNA-135b(miR-135b)、miR-148a-3p、miR-186-5p表达水平及其与新辅助化疗效果的相关性。方法:选取116例乳腺癌患者为病例组,均接受新辅助化疗,以21 d为1个周期,共化疗8个周期,根据化疗反应将患者分为耐药组(32例)和敏感组(84例),另选128例体检健康女性为对照组。比较病例组和对照组,耐药组和敏感组血清miR-135b、miR-148a-3p、miR-186-5p表达水平。采用Pearson相关性分析血清miR-135b、miR-148a-3p、miR-186-5p水平间的相关性。乳腺癌患者化疗效果的影响因素采用Logistic回归分析。血清miR-135b、miR-148a-3p、miR-186-5p对乳腺癌患者化疗耐药的预测价值通过受试者工作特征(ROC)曲线分析。结果:与对照组比较,病例组miR-135b、miR-148a-3p水平升高,血清miR-186-5p水平降低(均P<0.05)。耐药组血清miR-135b、miR-148a-3p水平高于敏感组,血清miR-186-5p水平低于敏感组(均P<0.05)。Pearson相关性分析结果显示,血清miR-135b与miR-148a-3p呈正相关,与miR-186-5p呈负相关,血清miR-148a-3p与miR-186-5p呈负相关(均P<0.05)。多因素Logistic回归分析显示,血清miR-135b、miR-148a-3p、miR-186-5p是乳腺癌患者化疗效果的影响因素(均P<0.05)。ROC曲线分析结果显示,血清miR-135b、miR-148a-3p、miR-186-5p联合预测化疗耐药的曲线下面积(AUC)高于三者单独预测AUC(均P<0.05)。结论:乳腺癌患者血清miR-135b、miR-148a-3p水平呈高表达,血清miR-186-5p水平呈低表达,三者水平变化与新辅助化疗效果有关,且三者联合检测对患者新辅助化疗耐药的预测价值更高。
Abstract:
Objective:To investigate the expression levels of serum microRNA-135b(miR-135b),miR-148a-3p and miR-186-5p in breast cancer patients and their correlation with the effect of neoadjuvant chemotherapy.Methods:A total of 116 patients with breast cancer were selected as the case group,and all received neoadjuvant chemotherapy,21 days as a cycle,a total of 8 cycles of chemotherapy.According to the chemotherapy response,patients were divided into the drug-resistant group(32 cases)and the sensitive group(84 cases),and 128 healthy women were selected as the control group.The expression levels of serum miR-135b,miR-148a-3p and miR-186-5p were compared between the case group and the control group,and between the drug-resistance group and the sensitive group.Pearson correlation analysis was used to analyze the correlation between serum miR-135b,miR-148a-3p and miR-186-5p levels.Logistic regression analysis was used to analyze the influencing factors of chemotherapy effect in breast cancer patients.The predictive value of serum miR-135b,miR-148a-3p and miR-186-5p for chemotherapy resistance in breast cancer patients was analyzed by receiver operating characteristic(ROC)curve.Results:Compared with the control group,the levels of miR-135b and miR-148a-3p in the case group were increased,and the level of serum miR-186-5p was decreased(all P<0.05).The levels of serum miR-135b and miR-148a-3p in the drug-resistant group were higher than those in the sensitive group,and the level of serum miR-186-5p was lower than that in the sensitive group(all P<0.05).Pearson correlation analysis showed that serum miR-135b was positively correlated with miR-148a-3p and negatively correlated with miR-186-5p,and serum miR-148a-3p was negatively correlated with miR-186-5p(all P<0.05).Multivariate Logistic regression analysis showed that serum miR-135b,miR-148a-3p and miR-186-5p were influencing factors of chemotherapy effect in breast cancer patients(all P<0.05).ROC curve analysis showed that the area under the curve(AUC)of the combination of serum miR-135b,miR-148a-3p and miR-186-5p for predicting chemotherapy resistance was higher than that of the three alone(all P<0.05).Conclusion:The levels of serum miR-135b and miR-148a-3p in breast cancer patients are highly expressed,and the level of serum miR-186-5p is low.The changes of the three levels are related to the effect of neoadjuvant chemotherapy,and the combined detection of the three has a higher predictive value for neoadjuvant chemotherapy resistance in patients.

参考文献/References:

[1] 宿娜,山周琦玥,辛毅.乳腺癌患者426例临床特征及危险因素分析[J].陕西医学杂志,2023,52(12):1707-1710.
[2] MEHRAJ U,DAR A H,WANI N A,et al.Tumor microenvironment promotes breast cancer chemoresistance[J].Cancer Chemother Pharmacol,2021,87(2):147-158.
[3] 武月升,宋彬.乳腺癌内分泌治疗耐药的影响因素探讨[J].医学研究杂志,2022,51(5):68-73.
[4] 冯秀梅,马兰,罗玉群,等.益气活血方对乳腺癌MCF-7细胞系增殖侵袭能力及miR-100表达水平影响的研究[J].陕西中医,2021,42(11):1527-1530.
[5] 汪伶俐,田武国,赵健洁,等.lncRNA NRON靶向miR-185-5p调节乳腺癌细胞化疗耐药性的机制研究[J].疑难病杂志,2022,21(10):1088-1095.
[6] 秦明明,浦春,冯钢,等.let-7i通过抑制K-Ras、Bcl2的表达降低乳腺癌细胞化疗耐药性[J].细胞与分子免疫学杂志,2019,35(11):992-999.
[7] 杨瑞祥,周全,陈慧敏,等.基于miR-181c-3p/STAT3通路探讨增液润燥汤治疗干燥综合征作用机制[J].陕西中医,2023,44(12):1698-1703.
[8] CSERNI G,CHMIELIK E,CSERNI B,et al.The new TNM-based staging of breast cancer[J].Virchows Arch,2018,472(5):697-703.
[9] 中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2017年版)[J].中国癌症杂志,2017,27(9):20-84.
[10] 白玲娇,陈小军,王婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239-1241,1245.
[11] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:Revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[12] 王成,王晓玲,汪旻琦,等.女贞莲桂白芍汤联合常规辅助化疗治疗三阴性乳腺癌术后疗效研究[J].陕西中医,2023,44(12):1735-1739.
[13] 麦嘉雯,林家丽,郑智超.多模态超声联合血清指标评估乳腺癌新辅助化疗病理缓解及预后[J].中国现代普通外科进展,2023,26(10):817-820.
[14] CHANG J C,CHANG H S,WU Y C,et al.Mitochondrial transplantation regulates antitumour activity,chemoresistance and mitochondrial dynamics in breast cancer[J].J Exp Clin Cancer Res,2019,38(1):30.
[15] 王慧,余嘉文,朱晨,等.NLR、PLR、LMR与乳腺癌新辅助化疗疗效及预后的关系研究[J].现代生物医学进展,2023,23(16):3118-3122.
[16] NATH A,MITRA S,MISTRY T,et al.Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer[J].Med Oncol,2021,39(1):14.
[17] ZHANG Y,XIA F,ZHANG F,et al.MiR-135b-5p enhances doxorubicin-sensitivity of breast cancer cells through targeting anterior gradient 2[J].J Exp Clin Cancer Res,2019,38(1):26.
[18] 冯燕枝,张景臣,刘薇.三阴性乳腺癌中miR-135b、LZTS1表达水平对评估新辅助化疗疗效的价值[J].热带医学杂志,2020,20(4):525-529,566.
[19] 李霞,梁海珊,程学,等.CXCL12/CXCR4轴通过调节自噬促进乳腺癌细胞对多柔比星的化疗抗性[J].中国免疫学杂志,2023,39(7):1446-1451.
[20] YU S,YU M,CHEN J,et al.Circ 0000471 suppresses the progression of ovarian cancer through mediating miR-135b-5p/dusp5 axis[J].Am J Reprod Immunol,2023,89(4):13651.
[21] LI H L,WANG C P,ZHANG Y,et al.Long non-coding RNA PVT1 facilitates cell migration and invasion by regulating miR-148a-3p and ROCK1 in breast cancer[J].Clin Transl Oncol,2022,24(5):882-891.
[22] 余喜梅,张雯捐,龚烨.血清miR-671-3p、miR-135b水平与老年乳腺癌患者化疗耐药性的相关性[J].国际检验医学杂志,2022,43(14):1766-1771.
[23] 陈元元,唐铁雷,程永刚,等.miR-148a-3p、miR-128、miR-588在乳腺癌中的表达情况及其与耐药性的关系[J].现代肿瘤医学,2019,27(12):2108-2113.
[24] 莫丹,陈喜裕,何婕,等.血清microRNA-186-5p、microRNA-328-5p表达和乳腺癌患者临床病理特征与新辅助化疗效果的关系[J].中国现代医学杂志,2023,33(5):9-15.
[25] HAO H,WANG B,YANG L,et al.MiRNA-186-5p inhibits migration,invasion and proliferation of breast cancer cells by targeting SBEM[J].Aging(Albany NY),2023,15(14):6993-7007.

相似文献/References:

[1]乔亚舜,吴瑛琦.乳腔镜腋窝淋巴结清扫术治疗早期乳腺癌临床研究[J].陕西医学杂志,2019,(4):473.
　QIAO Yashun,WU Yingqi..Clinical study of mammoscopic axillary lymph node dissection for early breast cancer patients[J].,2019,(5):473.
[2]谭兴利,陆伟辉,汤学文,等.乳腺癌患者超声检查中PSV、RI值与术后组织中MMP11、VEGF表达的相关性探讨[J].陕西医学杂志,2019,(5):617.
[3]韩丕华,宋张骏△,杨晓民,等.乳腺超声造影联合细针穿刺定位活检在判定乳腺癌新辅助化疗后腋窝淋巴结性质中的临床研究*[J].陕西医学杂志,2019,(7):842.
　HAN Pihua,SONG Zhangjun,YANG Xiaomin,et al.Application of breast contrast-enhanced ultrasonography combined with fine needle aspiration biopsy in determining the axillary lymph node properties after neoadjuvant chemotherapy for breast cancer[J].,2019,(5):842.
[4]蒋 敢,王 军,王会东△.舒芬太尼联合罗哌卡因肋间神经阻滞对乳腺癌患者术后镇痛、免疫功能及应激反应的影响*[J].陕西医学杂志,2019,(8):1077.
　JIANG Gan,WANG Jun,WANG Huidong..Effect of sufentanil plus ropivacaine intercostal nerve block on postoperative analgesia, immunity and stress response in patients with breast cancer[J].,2019,(5):1077.
[5]王群拴,黎小花△.核磁共振结合血清肿瘤标志物及细胞因子检测在〖JZ〗乳腺癌诊断中的应用价值研究*[J].陕西医学杂志,2019,(10):1295.
[6]韩丕华,袁 权△.乳腺癌患者白细胞介素-22表达水平对新辅助化疗后病理学完全缓解的预测价值*[J].陕西医学杂志,2020,49(7):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
　HAN Pihua,YUAN Quan..Predictive value of IL-22 expression level in breast cancer patients for pathological complete remission after neoadjuvant chemotherapy[J].,2020,49(5):889.[doi:DOI:10.3969/j.issn.10007377.2020.07.033]
[7]韩金怡,苏志勇.21基因检测对早期Luminal A型乳腺癌治疗指导作用研究[J].陕西医学杂志,2021,50(9):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
　HAN Jinyi,SU Zhiyong.Guiding role of 21-gene detection in treatment of early Luminal type A breast cancer[J].,2021,50(5):1081.[doi:DOI:10.3969/j.issn.1000-7377.2021.09.010]
[8]白玲娇,陈小军,王 婷.乳腺癌超声弹性成像评分与免疫组化指标表达水平相关性分析[J].陕西医学杂志,2021,50(10):1239.[doi:DOI:10.3969/j.issn.1000-7377.2021.10.015]
[9]郑 超,苏 娟,盛杰鑫,等.乳腺癌患者病灶血流时间-信号强度曲线类型、表观弥散系数与化疗疗效相关性分析[J].陕西医学杂志,2021,50(12):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
　ZHENG Chao,SU Juan,SHENG Jiexin,et al.Correlation between focal blood flow time-signal intensity curve type,apparent diffusion coefficient and chemotherapy efficacy in breast cancer patients[J].,2021,50(5):1521.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.013]
[10]李福平,王 茂,邱春丽,等.莱菔硫烷联合维生素D对乳腺癌细胞增殖及凋亡的影响[J].陕西医学杂志,2022,51(8):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]
　LI Fuping,WANG Mao,QIU Chunli,et al.Effect of sulforaphane combined with vitamin D on proliferation and apoptosis of breast cancer cells[J].,2022,51(5):916.[doi:DOI:10.3969/j.issn.1000-7377.2022.08.003]

备注/Memo

备注/Memo:
基金项目:黑龙江省卫生健康委员会科研项目(20230404080178)
更新日期/Last Update: 2024-05-06